BioScrip Company Profile (NASDAQ:BIOS)

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Hospitals, Clinics & Primary Care Services
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:BIOS
  • CUSIP: 09069N10
  • Web:
  • Market Cap: $355.69 million
  • Outstanding Shares: 120,982,000
Average Prices:
  • 50 Day Moving Avg: $2.66
  • 200 Day Moving Avg: $1.90
  • 52 Week Range: $0.98 - $3.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.70
  • P/E Growth: -0.78
Sales & Book Value:
  • Annual Revenue: $914.94 million
  • Price / Sales: 0.39
  • Book Value: ($0.40) per share
  • Price / Book: -7.35
  • EBIDTA: $25.34 million
  • Net Margins: -5.62%
  • Return on Assets: -6.39%
  • Debt-to-Equity Ratio: -9.40%
  • Current Ratio: 1.45%
  • Quick Ratio: 1.20%
  • Average Volume: 1.41 million shs.
  • Beta: 0.35
  • Short Ratio: 13.34
Frequently Asked Questions for BioScrip (NASDAQ:BIOS)

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip, Inc. (NASDAQ:BIOS) announced its earnings results on Thursday, May, 4th. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.04. The firm earned $217.80 million during the quarter, compared to analyst estimates of $230.23 million. BioScrip's revenue for the quarter was down 8.7% on a year-over-year basis. During the same period last year, the firm posted ($0.17) earnings per share. View BioScrip's Earnings History.

When will BioScrip make its next earnings announcement?

BioScrip is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for BioScrip.

Where is BioScrip's stock going? Where will BioScrip's stock price be in 2017?

3 equities research analysts have issued twelve-month target prices for BioScrip's shares. Their forecasts range from $3.00 to $4.50. On average, they expect BioScrip's share price to reach $3.67 in the next year. View Analyst Ratings for BioScrip.

What are analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:

  • 1. According to Zacks Investment Research, "Over the last one month, BioScrip has been trading above the broader Medical Output/Homecare industry. The market is upbeat about BioScrip’s announcement to continue to offer certain core product lines to UnitedHealthcare. We are also encouraged by the company’s progress for its new multi-faceted CORE plan to improve its financial position. Further, BioScrip successfully completed the Home Solutions’ integration within the last reported first quarter. The company expects core revenues at Home Solutions and continued core growth to prove accretive going forward. On the flip side, the company's year-over-year drop in revenues due to lower-than-expected core sales volumes is discouraging. Management’s 2017 guidance, which includes the negative impact of the Cures Act legislation, also adds to our concerns." (7/5/2017)
  • 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:

  • Daniel E. Greenleaf, President, Chief Executive Officer, Director
  • Stephen M. Deitsch, Chief Financial Officer, Senior Vice President, Treasurer
  • David Evans, Chief Operating Officer, Senior Vice President
  • Betty Y Jang, Senior Vice President, Chief Compliance Officer
  • C Britt Jeffcoat, Chief Accounting Officer, Vice President, Controller
  • Kathryn M. Stalmack, General Counsel
  • Scott J. Davido, Chief Implementation Officer
  • Michael G. Bronfein CPA, Director
  • Steven Neumann, Director
  • Christopher S. Shackelton, Director

Who owns BioScrip stock?

BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include GAMCO INVESTORS, INC. ET AL (10.37%), ARES MANAGEMENT LLC (9.20%), Roanoke Asset Management Corp NY (0.33%), Sheets Smith Wealth Management (0.10%) and Perkins Capital Management Inc. (0.06%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger and R Carter Pate. View Institutional Ownership Trends for BioScrip.

Who sold BioScrip stock? Who is selling BioScrip stock?

BioScrip's stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for BioScrip.

Who bought BioScrip stock? Who is buying BioScrip stock?

BioScrip's stock was bought by a variety of institutional investors in the last quarter, including Roanoke Asset Management Corp NY and Sheets Smith Wealth Management. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger and R Carter Pate. View Insider Buying and Selling for BioScrip.

How do I buy BioScrip stock?

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BioScrip stock can currently be purchased for approximately $2.94.

MarketBeat Community Rating for BioScrip (NASDAQ BIOS)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioScrip (NASDAQ:BIOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.67 (24.72% upside)

Analysts' Ratings History for BioScrip (NASDAQ:BIOS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
3/6/2017Jefferies Group LLCBoost Price TargetBuy$2.50 -> $3.00N/AView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
3/5/2016StephensReiterated RatingBuyN/AView Rating Details
8/12/2015Dougherty & CoLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
8/11/2015SunTrust Banks, Inc.DowngradeBuy -> Neutral$5.00 -> $2.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for BioScrip (NASDAQ:BIOS)
Earnings by Quarter for BioScrip (NASDAQ:BIOS)
Earnings History by Quarter for BioScrip (NASDAQ BIOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017($0.12)N/AView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioScrip (NASDAQ:BIOS)
2017 EPS Consensus Estimate: ($0.26)
2018 EPS Consensus Estimate: ($0.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.14)($0.08)($0.12)
Q2 20172($0.10)($0.06)($0.08)
Q3 20173($0.08)($0.04)($0.06)
Q4 20173($0.02)$0.00($0.01)
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.07)($0.07)($0.07)
Q4 20181$0.02$0.02$0.02
(Data provided by Zacks Investment Research)


Dividend History for BioScrip (NASDAQ:BIOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioScrip (NASDAQ:BIOS)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 83.06%
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.00View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.00View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.00View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.00View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.00View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.00View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.00View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.00View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.78View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioScrip (NASDAQ:BIOS)
Latest Headlines for BioScrip (NASDAQ:BIOS)
DateHeadline logo-$0.10 EPS Expected for BioScrip, Inc. (NASDAQ:BIOS) This Quarter - July 26 at 12:27 AM logoRoanoke Asset Management Corp Buys Emerson Electric Co, Eli Lilly and Co, Fortive Corp, Sells ... - July 20 at 6:10 PM logoBioScrip To Host Second Quarter Results Call - GlobeNewswire (press release) - July 17 at 4:50 PM logoBioScrip To Host Second Quarter Results Call - July 17 at 4:50 PM logoBioScrip, Inc. (BIOS) Upgraded to "Hold" at ValuEngine - July 16 at 5:14 PM logoBioScrip, Inc. (BIOS) Upgraded to Buy at Zacks Investment Research - July 5 at 12:38 PM logoBioScrip, Inc. (BIOS) Upgraded to Hold at Zacks Investment Research - July 2 at 12:02 PM logo Analysts Anticipate BioScrip, Inc. (NASDAQ:BIOS) Will Announce Quarterly Sales of $219.72 Million - July 1 at 8:17 AM logoBRIEF-BioScrip announces new senior note facilities - June 29 at 10:45 PM logoBioScrip, Inc. (BIOS) Expected to Announce Earnings of -$0.10 Per Share - June 29 at 8:34 PM logoQ4 2017 EPS Estimates for BioScrip, Inc. Lifted by Analyst (BIOS) - June 28 at 8:38 AM logoBioScrip, Inc. (BIOS) PT Raised to $3.50 at Barrington Research - June 26 at 11:00 AM logoReviewing The Ensign Group (ENSG) and BioScrip (BIOS) - June 25 at 12:17 PM logoHealthcare Stock Performance Review -- Brookdale Senior Living, BioScrip, Envision Healthcare, and Kindred Healthcare - June 14 at 10:43 AM logoShort Interest in BioScrip Inc (BIOS) Grows By 14.0% - June 11 at 7:14 AM logoWhy Is BioScrip (BIOS) Up 15.3% Since the Last Earnings Report? - Nasdaq - June 10 at 2:33 AM logoWhy Is BioScrip (BIOS) Up 15.3% Since the Last Earnings Report? - June 9 at 4:28 PM logoBioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $219.72 Million - June 7 at 9:50 AM logo Brokerages Expect BioScrip Inc (BIOS) Will Announce Earnings of -$0.10 Per Share - June 5 at 4:04 PM logoBUZZ-U.S. STOCKS ON THE MOVE-Atwood Oceanics, Protagonist ... - Nasdaq - May 30 at 9:01 PM logoBioScrip Provides Update on UnitedHealthcare Contract - GlobeNewswire (press release) - May 30 at 9:01 PM logoBRIEF-Bioscrip provides update on Unitedhealthcare contract - May 30 at 12:23 PM logoBioScrip Provides Update on UnitedHealthcare Contract - May 30 at 12:23 PM logoBioScrip Inc (BIOS) Short Interest Update - May 26 at 7:08 AM logoBioScrip to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release) - May 24 at 8:52 PM logoBioScrip to Present at the Jefferies 2017 Global Healthcare Conference - May 24 at 12:28 PM logoETFs with exposure to BioScrip, Inc. : May 23, 2017 - May 23 at 4:00 PM logoShort Interest in BioScrip Inc (BIOS) Expands By 1.7% - May 13 at 7:08 PM logoDull Q1 Earnings & Tough Industry Spell Trouble for BioScrip - Nasdaq - May 12 at 9:32 PM logo$219.72 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter - May 12 at 4:52 PM logoETFs with exposure to BioScrip, Inc. : May 11, 2017 - May 11 at 4:28 PM logoZacks Investment Research Downgrades BioScrip Inc (BIOS) to Sell - May 10 at 1:34 PM logoZacks: Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.09 Per Share - May 10 at 8:16 AM logoBioScrip, Inc. :BIOS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 3:56 PM logoBRIEF-Bioscrip reports first quarter 2017 financial results - May 6 at 1:58 AM logoBioScrip Inc (BIOS) Posts Earnings Results, Misses Estimates By $0.04 EPS - May 5 at 5:44 PM logoBioScrip Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 5 at 3:56 PM logoForm 4 BioScrip, Inc. For: May 02 Filed by: Coliseum Capital Management, LLC - - May 5 at 3:56 PM logoBioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss - Nasdaq - May 5 at 3:56 PM logoEdited Transcript of BIOS earnings conference call or presentation 4-May-17 1:00pm GMT - May 5 at 2:06 AM logoInvestor Network: BioScrip, Inc. to Host Earnings Call - May 4 at 4:03 PM logoBioScrip Reports First Quarter 2017 Financial Results - May 4 at 4:03 PM logoBioScrip reports 1Q loss - May 4 at 4:03 PM logoSomewhat Favorable News Coverage Likely to Impact BioScrip (BIOS) Stock Price - May 3 at 5:22 PM logoBioScrip Inc (BIOS) Set to Announce Quarterly Earnings on Thursday - May 2 at 11:24 AM logoBioScrip (BIOS) Getting Somewhat Negative Media Coverage, Report Finds - April 29 at 5:27 PM logoBioScrip (BIOS) Earns Daily Coverage Optimism Rating of 0.20 - April 26 at 7:02 PM logoHow a ‘Christmas miracle’ became a nightmare for heart-failure patients - April 25 at 12:37 PM logoBioScrip (BIOS) Earning Favorable News Coverage, Study Finds - April 23 at 1:23 PM logoBioScrip Announces CFO Transition - GlobeNewswire (press release) - April 20 at 9:02 PM



BioScrip (BIOS) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff